niraparib
glaxosmithkline
['zejula']
in the hrd population, zejula reduced the disease progression or death by 48% versus placebo. the estimated durable pfs was 24% in the zejula arm compared to 14% in patients on placebo. #esmo22 #esmo2022 #onctwitter #medtwitter #cancer #oncology
iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma